



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/592,961

09/08/2008

Henrik Stender

61057US(48497)

3779

86738

7590

01/14/2011

MCCARTER & ENGLISH, LLP BOSTON

265 Franklin Street

Boston, MA 02110

EXAMINER

THOMAS, DAVID C

ART UNIT

PAPER NUMBER

1637

MAIL DATE

DELIVERY MODE

01/14/2011

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 10/592,961	Applicant(s) STENDER ET AL.	
	Examiner DAVID C. THOMAS	Art Unit 1637	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 11 November 2010.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-41 is/are pending in the application.
- 4a) Of the above claim(s) 32-41 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-31 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date <u>9/15/2006</u> | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Election/Restrictions

1. Applicant's election without traverse of Group I, claims 1-31, in the reply filed on November 11, 2010 is acknowledged. Claims 32-41 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim.

Claim Objections

2. Claims 1-31 are objected to because of the following informalities: The fourth line of base claim 1 begins with "A mixture of two probes...". The claims should be a continuous sentence without uppercase headings. In addition, the probes are referred to as "Probe A" or "Probe b" in most instances in the claims, which is inconsistent with their designation as "probe A and probe B" in line 4 of claim 1. Appropriate correction is required.

Claim Rejections - 35 USC § 112

3. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

4. Claim 31 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. The claim recites the limitation "wherein the target sequence in a forensic technique such as prenatal screening, paternity testing, identity

Art Unit: 1637

confirmation or crime investigation”, which is indefinite since there is no active step in the claim.

Claim Rejections - 35 USC § 102

5. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

6. Claims 1-10, 18, 29 and 30 are rejected under 35 U.S.C. 102(b) as being anticipated by Yang et al. (Anal. Biochem. (1998) 259:272-274, listed on IDS of 9/15/2006).

Yang teaches a method for the analysis of a target sequence in a first sample (detection of human p53 mutations in samples was performed with an assay based on using labeled fluorescence resonance energy transfer (FRET) probes, p. 272, column 1, lines 8-12), said method comprising:

a. contacting the first sample with a mixture (samples included synthetic oligonucleotides containing DNA sequences corresponding to the wild-type and mutant forms of p53, p. 272, column 2, lines 30-33 and Figure 1, top and bottom sequence duplexes) comprising:

a mixture of two probes (probe A and probe B) (fluorescently labeled pyrimidine-rich probes were prepared by automated DNA synthesis, p. 272, column 2, lines 33-37), wherein:

i) Probe A is comprised of a nucleotide sequence, directed to a region of the target sequence and is labeled with a fluorophore at the end which, upon hybridization is closest to the adjacent target region for Probe B (probe-2 is labeled with a donor moiety, 5-carboxyfluorescein (FL) at the 5' end and binds to form a DNA triplex to both the wild-type and mutant sequences, p. 272, column 1, lines 23-29 and column 2, 43-47 and Figure 1, middle right probe binding to right region of target); and

ii) Probe B is comprised of a nucleotide sequence, which cohybridizes to a region of the target sequence adjacent to the target region of Probe A and is labeled with a quencher which, upon hybridization is closest to the adjacent target region for Probe A (probe-1 is labeled with an acceptor moiety, tetramethylrhodamine (TMR), at the 3' end and binds to form a DNA triplex to the wild-type sequence but only pairs with 7 of 12 bases in the mutant sequence, p. 272, column 2, lines 23-26 and 43-47 and Figure 1, middle left probe binding to left region of target),

b. measuring fluorescence following cohybridization of Probe A and Probe B to the target sequence, under suitable hybridization conditions, wherein the presence or amount of target sequence present in the first sample can be negatively correlated with the fluorescence of the fluorophore on Probe A (the presence of the wild-type sequence causes a decrease in fluorescence of the fluorescein-labeled probe 2, indicated by a decrease in emission at 520 nm, resulting from efficient binding of the quencher probe-1, p. 273, column 1, lines 17-24 and Figure 2, top panel).

With regard to claim 2, Yang teaches a method wherein the fluorescence is measurably different than a control (no decrease in emission at 520-nm is noted with the mutant target sequence, p. 273, column 1, lines 24-25 and Figure 2, top panel).

With regard to claim 3, Yang teaches a method wherein the control is a positive control, a negative control, a no target control or a second sample (the mutant sequence serves as a negative control since no energy transfer is observed compared with the wild-type sequence, p. 273, column 1, lines 17-25 and Figure 2, top panel).

With regard to claim 4, Yang teaches a method wherein the fluorescence is taken to be indicative of an increase in target concentration, a structural difference between sample and control target sequences or a change in the state of the target sequence (the decrease in fluorescence noted in the presence of the wild-type sequence is indicative of presence of a sequence that is deleted in the mutant sequence, and therefore the quencher probe binds efficiently to the wild-type but not the mutant target, p. 272, column 2, lines 23-29 and p. 273, column 1, lines 17-25).

With regard to claims 5 and 7, Yang teaches a method wherein the structural difference between sample and control target sequences is at least one of a nucleobase insertion, nucleobase deletion, genetic polymorphism, splice variation, amplification or mutation (the structural difference between the wild-type and mutant target sequences is an 8-bp deletion at the third position of codon 285 within exon 8 of the human p53 gene, p. 272, column 2, lines 7-15).

With regard to claim 6, Yang teaches a method wherein the change in target state is due to at least one of degradation, methylation, folding, hybridization, or

Art Unit: 1637

association of the target sequence with protein (the p53 deletion results in differential hybridization of the quencher probe-1 with the mutant sequence versus the wild-type sequence, p. 273, column 1, lines 17-25 and also see Figures 1 and 2).

With regard to claim 8, Yang teaches a method wherein the method is used to detect target sequence in a closed tube (homogeneous) assay (the FRET-based probe binding assay used to distinguish wild-type from mutant target sequences is performed in a spectrophotometer such that after the dye-labeled probes are allowed to equilibrate with the unlabeled target DNA solutions, the emission intensities are measured in a closed tube format, p. 273, column 1, lines 4-14).

With regard to claim 9, Yang teaches a method wherein the method is used to detect a nucleic acid comprising a target sequence wherein said nucleic acid has been synthesized or amplified in a reaction occurring in the closed tube (homogeneous) assay (target DNA may be synthesized to construct duplex target models corresponding to the wild-type and 8-bp deletion mutant forms of p53, p. 272, column 2, lines 30-33 and Figure 1, top and bottom sequence duplexes).

With regard to claim 10, Yang teaches a method wherein preferred nucleic acid synthesis or nucleic acid amplification reactions are selected from the group consisting of: Polymerase Chain Reaction (PCR), Ligase Chain Reaction (LCR), Strand Displacement Amplification (SDA), Transcription-Mediated Amplification (TMA), Rolling Circle Amplification (RCA) and Q beta replicase (target samples may also be prepared by PCR amplification and hybridized to the dye-labeled probes to detect mutant or wild-type sequences, p. 274, lines 13-35).

With regard to claim 18, Yang teaches a method wherein the method is used to diagnose a condition of medical interest (the FRET-based assay was applied to screen clinical DNA samples, p. 274, column 1, lines 3-4).

With regard to claims 29 and 30, Yang teaches a method wherein the sample comprises a target sequence which is indicative for a genetically based disease or is indicative for a predisposition to a genetically based disease or associated with a disease selected from the group consisting of 5-Thalassemia, sickle cell anemia, Factor-V Leiden, cystic fibrosis and cancer related targets such as p53, p10, BRC-1 and BRC-2 (the FRET-based assay was applied to screen clinical DNA samples obtained from patients diagnosed pathologically with hepatocellular carcinoma using primers and probes targeted to exon 8 of the p53 gene, p. 274, column 1, lines 3-35).

Claim Rejections - 35 USC § 103

7. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

8. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was

Art Unit: 1637

not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

9. Claim 11 is rejected under 35 U.S.C. 103(a) as being unpatentable over Yang et al. (Anal. Biochem. (1998) 259:272-274) in view of Johansen et al. (U.S. Patent No. 6,441,152).

Yang teaches the limitations of claims 1-10, 18, 29 and 30, as discussed above. However, Yang does not disclose methods wherein the PCR reaction is an asymmetric PCR reaction.

Johansen teaches methods for detecting nucleic acid targets after binding to matrices containing non-nucleotide probes such as PNA probes (see Abstract and column 8, lines 60-65). Johansen further teaches that the binding of nucleic acids to the matrices may be monitored by closed-tube PCR assays such as self-indicating assays that measure fluorescence within the closed reaction tube after amplification and binding to complementary bound probes (column 35, lines 1-14). Johansen further teaches that the amplification may be asymmetric PCR to favor production of a significant excess of single-stranded nucleic acid (column 35, lines 53-60).

It would have been prima facie obvious to one having ordinary skill in the art at the time the invention was made to combine the methods of Yang and Johansen since Johansen teaches a method for amplification of target nucleic acids that is highly compatible with the FRET probes taught by Yang for detection of mutant and wild-type

Art Unit: 1637

target sequences. Thus, an ordinary practitioner would have been motivated to use the methods for asymmetric PCR in preparation of target nucleic acids which can then be detected in a closed tube assay using the FRET probes of Yang. The asymmetric PCR method taught by Johansen favors production of a significant excess of single-stranded nucleic acid such that "it is possible to choose which strand of the amplicon are preferentially amplified by judicious adjustment of the ratio of 5' and 3' primers" (Johansen, column 35, lines 53-60). Thus, probes may be designed with energy transfer labels attached to the probe termini as taught by Yang that hybridize specifically to the preferentially amplified strand, which is then detected as a decrease in fluorescence of the donor moiety of one of the FRET probes.

10. Claims 12-17, 19-28 and 31 are rejected under 35 U.S.C. 103(a) as being unpatentable over Yang et al. (Anal. Biochem. (1998) 259:272-274) in view of Livak et al. (U.S. Patent Pub. No. 2005/0053979).

Yang teaches the limitations of claims 1-10, 18, 29 and 30, as discussed above. However, Yang does not disclose methods wherein the target or probes are immobilized to a surface such as an array or wherein one or both probes are blocking probes or linear beacons and/or comprise PNA or LNA. Yang also does not disclose detecting, identifying or qualifying the presence or amount of one or more species or types of a microorganism in the sample, wherein the method is used to determine the effect of antimicrobial agents on the growth of one or more microorganisms in the sample. Yang also does not disclose a method wherein the target sequence in a

Art Unit: 1637

forensic technique such as prenatal screening, paternity testing, identity confirmation or crime investigation.

Livak teaches methods for design and making of oligonucleotide probes comprising universal base analogues for use in nucleic acid hybridization assays, and may also comprise other oligomeric structures such as locked nucleic acids (LNA) and peptide nucleic acids (PNA) (see Abstract and paragraph 36, lines 1-20). The probes may be labeled with energy transfer labels to form FRET probes suitable for use in real-time PCR analysis or other probe-hybridization based assays (paragraph 187, lines 1-6 and paragraph 222, lines 1-11). Energy-transfer probes can be provided as pairs of probes with donor and acceptor fluorophore moieties attached to ends of the same probe or on separate probes, wherein changes in a detectable signal from the donor or acceptor moieties result from hybridization, usually as an increase in measurable fluorescence (paragraph 216, lines 1-11, paragraph 223, lines 1-12, paragraph 224, lines 1-12 and paragraph 225, lines 1-23).

Specifically, with regard to claims 12, 13, 26 and 27, Livak teaches a method wherein the method further comprises contacting the sample with at least one blocking probe and/or hybridizing the blocking probe to non-target sequences, wherein the blocking probe is PNA or LNA (probes of the invention may also be used as unlabeled blocking probes to bind non-target sequences more favorably than labeled probes, paragraph 281, lines 1-4 and 8-11 and paragraph 281, lines 1-9; probes of the invention may comprise PNA or LNA, though blocking probes are preferentially PNA probes, paragraph 36, lines 15-20 and paragraph 281, lines 4-6).

With regard to claims 14-17, Livak teaches a method wherein the method further comprises detecting, identifying or qualifying the presence or amount of one or more species or types or a taxonomic group of a microorganism in the sample, and wherein the method is used to determine the effect of antimicrobial agents on the growth of one or more microorganisms in the sample (methods of the invention are used for identification of pathogens such as viruses, bacteria and eucarya in clinical samples, and for measuring the effects of products used to treat infected subjects during therapy monitoring and in pharmacogenomic and pharmacogenetic studies, paragraph 276, lines 1-17 and paragraph 277, lines 1-8).

With regard to claims 19-21, Livak teaches a method wherein the target sequence or Probe A is immobilized to a surface, such as an array (probes may be immobilized to a solid support to form an array or chip of oligomers, paragraph 264, lines 1-9 and paragraph 265, lines 1-15, and one or more target sequences are captured on the array by hybridization to complementary probes at specific locations for identification of the target by determining the location of a detectable signal generated on the array, paragraph 269, lines 1-13).

With regard to claims 22-25, Livak teaches a method wherein Probe A or Probe B is PNA or LNA or a nucleic acid comprising LNA (probes may comprise oligomeric backbone structures of any type, including LNA and PNA, paragraph 36, lines 15-20 and paragraph 88, lines 1-11).

With regard to claim 28, Livak teaches a method wherein at least one of the probes is a linear PNA beacon (probes may comprise a PNA backbone structure,

Art Unit: 1637

paragraph 157, lines 1-14, and may also be labeled with suitable energy transfer pairs to form a linear or molecular beacon to detect target nucleic acids by hybridization, paragraph 221, lines 1-9).

With regard to claim 31, Livak teaches a method wherein the target sequence in a forensic technique such as prenatal screening, paternity testing, identity confirmation or crime investigation (the methods can be used for identification of nucleic acid sequences in biological organisms, such as is useful in paternity testing and human identification, paragraph 7, lines 1-6 and paragraph 276, lines 1-3).

It would have been prima facie obvious to one having ordinary skill in the art at the time the invention was made to combine the methods of Yang and Livak since both references teach methods of nucleic acid hybridization using labeled probes, and measuring hybridization either by negative (Yang) or positive (Livak) changes in fluorescence of the donor moiety of a pair of FRET probes. Thus, an ordinary practitioner would have been motivated to combine the methods of using FRET-labeled probes of Livak that may also comprise LNA or PNA in the FRET-based methods of Yang since probes containing these non-natural modifications possess exceptional hybridization specificity and affinity, and are not known to be a substrates for enzymes such as polymerases or nucleases (Livak, paragraph 158, lines 4-7 and paragraph 159, lines 1-4). The probes of Livak are also useful as unlabeled blocking probes since such probes are able to suppress the binding of labeled probes to non-target sequences that might be present in an assay and otherwise interfere with the performance of the assay (Livak, paragraph 282, lines 14-20). Finally, the probes of Livak are useful for detecting

Art Unit: 1637

a variety of nucleic acid targets, including those of microorganisms or in samples used in paternity testing and human identification (paragraph 7, lines 1-6 and paragraph 276, lines 1-17). Any of these probes may be designed with energy transfer labels attached to the probe termini as taught by Yang for use in nucleic acid hybridization assays that measure successful hybridization by the decrease in fluorescence of the donor moiety of one of the FRET probes.

Conclusion

11. Claims 1-31 are rejected. No claims are allowable.

Correspondence

12. Any inquiry concerning this communication or earlier communications from the examiner should be directed to David C. Thomas whose telephone number is 571-272-3320 and whose fax number is 571-273-3320. The examiner can normally be reached on 5 days, 9-5:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached on 571-272-0782. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/David C Thomas/
Examiner, Art Unit 1637

/Kenneth R Horlick/
Primary Examiner, Art Unit 1637